Genexol inj. applicable to stomach cancer as additional indication

Published: 2004-03-08 06:59:00

Updated: 2004-03-08 06:59:00

Samyang Corporation said that Genexol (paclitaxel) inj., a chemotherapy that is given as a treatment for some types of cancer such as ovarian, breast and non-small cell lung cancer, was approved from the Korea Food and Drug Administration as an additional treatment of stomach cancer on February 2...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK